Comparing daily doses of aspirin to prevent blood clots after joint surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates whether taking 81 mg of aspirin once daily is as effective as taking it twice daily for preventing venous thromboembolism (VTE) in patients undergoing total hip or knee arthroplasty. The study aims to determine the optimal dosing strategy for aspirin chemoprophylaxis in this patient population. Participants will be monitored for the occurrence of blood clots following their surgery. The trial is designed to provide insights into the most effective aspirin regimen for reducing VTE risk.

Why it matters

Who can join: the full rules

Inclusion criteria:

* \> 18 years of age
* Planning to undergo a primary total hip or knee arthroplasty

Exclusion Criteria:

* High risk patients for VTE as defined by:

  * History of venous thromboembolism
  * Active malignancy
  * Known pro thrombotic condition
* BMI \> 40
* Patients requiring anticoagulation for pre-existing conditions
* Patients with the contraindication for use of aspirin or nonsteroidal antiinflammatory drugs for reasons such as peptic ulcer disease, intolerance, others.
* Patients not fluent in the language of the informed consent form
* Prisoners
* Pregnancy
* Reported to have mental illness or belonging to a vulnerable population

Where it's running

• University of Miami Hospital
  Miami, Florida, United States Recruiting

Study contacts

• Principal investigator: Victor Hernandez, MD — University of Miami
• Study coordinator: Ramakanth Yakkanti, MD
• Email: ramakanth.yakkanti@jhsmiami.org
• Phone: 502-689-3127

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• DoACs vs LMWH for blood flow after knee replacement

  This study tests whether rivaroxaban, apixaban, or LMWH work differently to support blood flow in the legs after total knee replacement in adults.

  Recruiting Military Hospital of Tunis · Tunis, Tunis Governorate · NCT07869615

• Prognostic value of the 2026 AHA/ACC PE classification in ED patients with acute PE

  This study tests whether the 2026 AHA/ACC five-category PE classification helps predict 30-day major adverse pulmonary embolism events in adults with acute PE presenting to the ED.

  Recruiting Marmara University Pendik Training and Research Hospital · Istanbul · NCT07805616

• Screening for blood clots in adults with acute heart failure

  This trial tests whether a guideline-based screening approach can detect pulmonary embolism in adults admitted with acute heart failure.

  Recruiting University Hospital, Angers · Agen and 9 other locations · NCT07499661

• Blood test and software to guide treatment for venous thromboembolism

  This project tests whether a blood-based ctDNA test combined with a software risk score can predict if VTE will come back in adults with cancer-associated DVT or PE who have finished 3–12 months of anticoagulation.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT07399977

• Aspiration thrombectomy with the Symphony or Prodigy devices

  This project will try the Symphony and Prodigy aspiration thrombectomy devices to remove arterial, venous, or pulmonary blood clots in adults.

  Recruiting at 13 sites Imperative Care, Inc. · Huntsville, Alabama and 12 other locations · NCT07350499

• Combining European cohort data to find biomarkers that guide treatment for venous thromboembolism

  This project combines clinical, biological and imaging data from European patient cohorts to try to find biomarkers that predict clot recurrence, bleeding, or death in people with venous thromboembolism.

  Recruiting University Hospital, Brest · Brest · NCT07328152

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.